IFNG and colorectal carcinoma: Multimodal therapies targeting IFN pathways (e.g., IFN-γ combined with immune checkpoint blockade) or downstream PCD effector molecules (e.g., ferroptosis inducers) may overcome treatment bottlenecks in pMMR/MSS-type CRC (207, 210, 211).